PubRank

Eric J Topol

Author PubWeight™ 566.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 18.25
2 Assessing the impact of population stratification on genetic association studies. Nat Genet 2004 16.28
3 Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009 12.11
4 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 11.06
5 Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol 2009 9.59
6 Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011 6.90
7 Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003 6.85
8 Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 2009 6.85
9 Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003 6.84
10 Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011 6.39
11 Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004 6.28
12 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature 2011 6.25
13 Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003 5.89
14 A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003 5.51
15 Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003 5.34
16 The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004 5.31
17 Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004 5.11
18 Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002 5.04
19 Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol 2009 4.80
20 Can mobile health technologies transform health care? JAMA 2013 4.75
21 Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 4.74
22 Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003 4.72
23 A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2005 4.45
24 N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003 4.31
25 Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007 4.30
26 Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005 4.23
27 Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 2008 4.11
28 Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010 3.97
29 Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008 3.64
30 Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003 3.38
31 Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003 3.34
32 Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med 2010 3.17
33 Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005 3.05
34 Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 2002 3.01
35 Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011 2.98
36 Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004 2.97
37 Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med 2012 2.91
38 Arthritis medicines and cardiovascular events--"house of coxibs". JAMA 2004 2.89
39 Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Res 2010 2.84
40 Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2005 2.80
41 Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008 2.61
42 Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005 2.59
43 Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007 2.56
44 Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 2004 2.54
45 Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol 2007 2.47
46 International differences in evolution of early discharge after acute myocardial infarction. Lancet 2004 2.47
47 A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007 2.47
48 The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 2011 2.43
49 Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet 2004 2.36
50 Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol 2009 2.32
51 An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007 2.31
52 Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010 2.27
53 Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005 2.26
54 The importance of phase information for human genomics. Nat Rev Genet 2011 2.25
55 Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004 2.24
56 Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med 2010 2.23
57 The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol 2010 2.19
58 Sex differences in mortality following acute coronary syndromes. JAMA 2009 2.17
59 Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 2003 2.17
60 Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003 2.06
61 Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008 2.05
62 The genetics of health. Nat Genet 2006 2.04
63 Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006 2.02
64 Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics 2005 2.01
65 A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol 2010 1.98
66 Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012 1.96
67 Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005 1.94
68 Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 2005 1.89
69 Impact of direct-to-consumer genomic testing at long term follow-up. J Med Genet 2013 1.86
70 A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. Proc Natl Acad Sci U S A 2009 1.84
71 Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009 1.80
72 Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009 1.77
73 Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study. PLoS Genet 2010 1.76
74 Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009 1.76
75 Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003 1.75
76 Cardiology and emergency medicine: united we stand, divided we fall. Ann Emerg Med 2002 1.72
77 Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002 1.70
78 Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007 1.66
79 Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002 1.65
80 Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet 2004 1.65
81 Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2009 1.64
82 Direct-to-consumer personalized genomic testing. Hum Mol Genet 2011 1.61
83 Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation. J Med Genet 2013 1.61
84 Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. Am J Cardiol 2002 1.60
85 Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol 2006 1.60
86 Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003 1.59
87 Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007 1.59
88 Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004 1.58
89 Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002 1.58
90 Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003 1.55
91 Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J 2005 1.54
92 Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am Heart J 2006 1.53
93 Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol 2003 1.52
94 Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv 2010 1.51
95 The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J 2009 1.49
96 An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet 2007 1.48
97 Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2011 1.47
98 Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002 1.47
99 Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. Ann Neurol 2014 1.47
100 The lost decade of nesiritide. N Engl J Med 2011 1.45
101 Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv 2010 1.45
102 Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012 1.43
103 Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004 1.42
104 Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J 2005 1.42
105 Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 2005 1.42
106 Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol 2003 1.42
107 Intensive statin therapy--a sea change in cardiovascular prevention. N Engl J Med 2004 1.41
108 The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol 2004 1.40
109 A matter of life and death? The Heart Protection Study and protection of clinical trial participants. Control Clin Trials 2003 1.40
110 Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. Catheter Cardiovasc Interv 2002 1.39
111 Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 2005 1.39
112 Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol 2005 1.39
113 Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation 2003 1.39
114 Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003 1.38
115 Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). Am J Cardiol 2002 1.37
116 Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Med Genomics 2011 1.37
117 Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2009 1.35
118 Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J 2005 1.34
119 Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004 1.34
120 Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 2006 1.33
121 Is pocket mobile echocardiography the next-generation stethoscope? A cross-sectional comparison of rapidly acquired images with standard transthoracic echocardiography. Ann Intern Med 2011 1.32
122 Future use of genomics in coronary artery disease. J Am Coll Cardiol 2007 1.31
123 Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012 1.30
124 Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002 1.30
125 Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2001 1.30
126 A robust hybrid between genetic algorithm and support vector machine for extracting an optimal feature gene subset. Genomics 2005 1.30
127 Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. Ann Emerg Med 2002 1.25
128 Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. Circulation 2004 1.24
129 The KIF6 collapse. J Am Coll Cardiol 2010 1.21
130 The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med 2008 1.21
131 Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 2002 1.19
132 Identification of new genes differentially expressed in coronary artery disease by expression profiling. Physiol Genomics 2003 1.19
133 Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2001 1.17
134 In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med 2003 1.17
135 Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012 1.16
136 Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004 1.15
137 Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2002 1.13
138 Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002 1.13
139 Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level. Genome Biol 2010 1.12
140 Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002 1.12
141 Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 2003 1.12
142 Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol 2003 1.11
143 Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. Circulation 2003 1.11
144 Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002 1.10
145 The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008 1.10
146 Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005 1.09
147 The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 2006 1.09
148 Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012 1.08
149 Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet 2003 1.08
150 The unmet need of education in genomic medicine. Am J Med 2012 1.08
151 Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics 2003 1.07
152 Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J 2002 1.07
153 The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009 1.07
154 Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004 1.07
155 Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008 1.07
156 The next phase in human genetics. Nat Biotechnol 2011 1.06
157 Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004 1.06
158 The resequencing imperative. Nat Genet 2007 1.05
159 Pharmacogenomics in cardiovascular diseases. Prog Cardiovasc Dis 2002 1.05
160 In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol 2007 1.04
161 Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. Am J Med 2006 1.04
162 Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009 1.03
163 Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006 1.02
164 Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease. J Med Genet 2006 1.02
165 Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J 2009 1.02
166 A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003 1.02
167 The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 2012 1.02
168 A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) trial. Am Heart J 2012 1.01
169 Genetic determinants of phenotypic diversity in humans. Genome Biol 2008 1.00
170 Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. Blood 2005 1.00
171 Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke 2011 1.00
172 Need to test the arterial inflammation hypothesis. Circulation 2002 0.99
173 Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. Am Heart J 2003 0.99
174 Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization. Catheter Cardiovasc Interv 2004 0.99
175 Role of stem cell homing in myocardial regeneration. Int J Cardiol 2004 0.99
176 Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 2005 0.98
177 Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old. Am J Cardiol 2003 0.98
178 International variation in the use of evidence-based medicines for acute coronary syndromes. Eur Heart J 2003 0.98
179 Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. Card Electrophysiol Rev 2003 0.98
180 Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002 0.98
181 Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med 2007 0.98
182 Deficiency of LRP8 in mice is associated with altered platelet function and prolonged time for in vivo thrombosis. Thromb Res 2008 0.98
183 Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. J Cardiovasc Transl Res 2012 0.97
184 Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2013 0.97
185 Annotating individual human genomes. Genomics 2011 0.97
186 Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 2003 0.96
187 Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004 0.96
188 Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J 2008 0.96
189 Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 2005 0.95
190 Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med 2003 0.95
191 Thrombospondins, their polymorphisms, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007 0.95
192 Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Med 2014 0.95
193 Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin. Eur J Hum Genet 2008 0.95
194 Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. FASEB J 2005 0.95
195 Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Mol Ther 2003 0.95
196 Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. JAMA 2003 0.95
197 Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002 0.94
198 Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. J Am Coll Cardiol 2004 0.94
199 Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 2004 0.94
200 Emerging genomic applications in coronary artery disease. JACC Cardiovasc Interv 2011 0.93
201 Genomic information as a behavioral health intervention: can it work? Per Med 2011 0.93
202 Aspirin resistance and a single gene. Am J Cardiol 2005 0.93
203 Clinical trials--multiple treatments, multiple end points, and multiple lessons. JAMA 2003 0.92
204 ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy). Am J Cardiol 2004 0.92
205 Multivariate sib-pair linkage analysis of longitudinal phenotypes by three step-wise analysis approaches. BMC Genet 2003 0.92
206 Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol 2005 0.91
207 Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. Am Heart J 2002 0.91
208 Clinical implications of human population differences in genome-wide rates of functional genotypes. Front Genet 2012 0.90
209 Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J 2004 0.90
210 Outcomes in African Americans and whites after percutaneous coronary intervention. Am J Med 2005 0.90
211 Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol 2003 0.90
212 Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004 0.90
213 iMedEd: the role of mobile health technologies in medical education. Acad Med 2014 0.90
214 Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J 2008 0.90
215 The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. Eur Heart J 2006 0.89
216 Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol 2004 0.89
217 The fibrillin-1 gene: unlocking new therapeutic pathways in cardiovascular disease. Heart 2012 0.89
218 Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 2002 0.89
219 Comparative gene expression analysis between coronary arteries and internal mammary arteries identifies a role for the TES gene in endothelial cell functions relevant to coronary artery disease. Hum Mol Genet 2011 0.89
220 Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. J Invasive Cardiol 2007 0.89
221 Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002 0.88
222 Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol 2005 0.88
223 Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke 2006 0.88
224 Rebooting cancer tissue handling in the sequencing era: toward routine use of frozen tumor tissue. JAMA 2013 0.88
225 Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. Am J Cardiol 2003 0.87
226 The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002 0.87
227 Mortality, kidney disease and cardiac procedures following acute coronary syndrome. Nephrol Dial Transplant 2007 0.87
228 Genetic structure of community acquired methicillin-resistant Staphylococcus aureus USA300. BMC Genomics 2012 0.87
229 Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004 0.87
230 Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002 0.87
231 Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol 2002 0.87
232 Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model. Yonsei Med J 2002 0.86
233 Genetic linkage analysis of longitudinal hypertension phenotypes using three summary measures. BMC Genet 2003 0.86
234 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv 2009 0.86
235 Molecular mechanisms of myocardial infarction. Curr Probl Cardiol 2005 0.86
236 An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial. Am J Med 2003 0.86
237 Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J 2002 0.86
238 Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 2009 0.85
239 Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. Am J Cardiol 2011 0.85
240 Autologous cell transplantation for the treatment of damaged myocardium. Prog Cardiovasc Dis 2002 0.85
241 Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. J Biol Chem 2004 0.85
242 Characteristics of genomic test consumers who spontaneously share results with their health care provider. Health Commun 2013 0.85
243 Genome scanning and cardiovascular disease. Heart 2008 0.85
244 Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events. Am J Cardiol 2007 0.85
245 Relation of insurance status to performance of coronary angiography in patients with unstable angina pectoris or acute myocardial infarction. Am J Cardiol 2003 0.85
246 Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009 0.85
247 Multi-allelic haplotype association identifies novel information different from single-SNP analysis: a new protective haplotype in the LRP8 gene is against familial and early-onset CAD and MI. Gene 2013 0.85
248 Miscues on the "lack of MEF2A mutations" in coronary artery disease. J Clin Invest 2005 0.84
249 Impact of female sex on outcome after percutaneous coronary intervention. Am Heart J 2004 0.84
250 Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005 0.84
251 Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol 2005 0.84
252 The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. Am Heart J 2005 0.84
253 Medicine unplugged: the future of laboratory medicine. Clin Chem 2012 0.84
254 The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol 2002 0.84
255 Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. Value Health 2009 0.84
256 Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovasc Interv 2012 0.83
257 Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002 0.83
258 How Consumers and Physicians View New Medical Technology: Comparative Survey. J Med Internet Res 2015 0.83
259 Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry. Eur Heart J 2003 0.83
260 Thyrotoxicosis and the cardiovascular system: subtle but serious effects. Cleve Clin J Med 2003 0.83
261 Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Heart J 2003 0.83
262 The big medical data miss: challenges in establishing an open medical resource. Nat Rev Genet 2015 0.83
263 Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. Am J Cardiol 2006 0.82
264 The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 2005 0.82
265 Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv 2009 0.82
266 Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis. J Cardiovasc Pharmacol Ther 2005 0.82
267 Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion. Thromb Haemost 2002 0.82
268 Gaining insights in coronary disease genomics. J Am Coll Cardiol 2008 0.82
269 Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. Am J Cardiol 2005 0.82
270 Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 2006 0.81
271 Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. Am J Cardiol 2002 0.81
272 Genetic testing for coronary heart disease: the approaching frontier. Expert Rev Mol Diagn 2002 0.81
273 Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. J Am Coll Cardiol 2004 0.81
274 Creation of a large-scale genetic data bank for cardiovascular association studies. Am Heart J 2005 0.81
275 Genotype-based risk and pharmacogenetic sampling in clinical trials. J Biopharm Stat 2010 0.81
276 A genome-wide linkage scan identifies multiple quantitative trait loci for HDL-cholesterol levels in families with premature CAD and MI. J Lipid Res 2010 0.81
277 Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003 0.81
278 The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice. Catheter Cardiovasc Interv 2006 0.81
279 The sad story of Vioxx, and what we should learn from it. Cleve Clin J Med 2004 0.81
280 Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. J Am Coll Cardiol 2002 0.80
281 Comment on "the predictive capacity of personal genome sequencing". Sci Transl Med 2012 0.80
282 Association of direct-to-consumer genome-wide disease risk estimates and self-reported disease. Genet Epidemiol 2011 0.80
283 Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol 2006 0.80
284 Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke 2010 0.80
285 Catapulting clopidogrel pharmacogenomics forward. Nat Med 2011 0.80
286 Identification of a novel locus for triglyceride on chromosome 1p31-32 in families with premature CAD and MI. J Lipid Res 2008 0.79
287 Pathobiology of atherosclerosis: are there racial and ethnic differences? Rev Cardiovasc Med 2004 0.79
288 Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 2006 0.79
289 Molecular genetics of atrial fibrillation. Genome Med 2009 0.79
290 Genome-wide association of implantable cardioverter-defibrillator activation with life-threatening arrhythmias. PLoS One 2012 0.79
291 Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 2002 0.79
292 An ensemble method for gene discovery based on DNA microarray data. Sci China C Life Sci 2004 0.79
293 Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation 2002 0.79
294 Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol 2004 0.79
295 Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am Heart J 2006 0.79
296 Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. Am Heart J 2004 0.79
297 Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. Am J Cardiol 2004 0.79
298 Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. J Am Coll Cardiol 2011 0.79
299 Convergence of atherosclerosis and alzheimer's disease: Cholesterol, inflammation, and misfolded proteins. Discov Med 2004 0.79
300 Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight. Curr Control Trials Cardiovasc Med 2001 0.79
301 Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. Eur Heart J 2007 0.79
302 Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. Eur Heart J 2005 0.78
303 Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol 2003 0.78
304 Identification of atherosclerosis-modifying genes: pathogenic insights and therapeutic potential. Expert Rev Cardiovasc Ther 2006 0.78
305 Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. Am J Cardiol 2008 0.78
306 Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. J Am Coll Cardiol 2004 0.78
307 Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. J Am Coll Cardiol 2002 0.78
308 Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscler Thromb Vasc Biol 2002 0.78
309 Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting. Am J Cardiol 2005 0.78
310 Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol 2004 0.78
311 Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002 0.78
312 CYP2C19 genotype and cardiovascular events. JAMA 2012 0.78
313 The arterial inflammation hypothesis. Arch Intern Med 2002 0.77
314 Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. Am Heart J 2007 0.77
315 Redefining risk in acute coronary syndromes using molecular medicine. J Am Coll Cardiol 2007 0.77
316 Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol 2002 0.77
317 Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med 2010 0.77
318 High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart 2011 0.77
319 Primary percutaneous coronary intervention vs. fibrinolytic therapy for acute ST-elevation myocardial infarction in the elderly. Am J Geriatr Cardiol 2006 0.77
320 Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002 0.77
321 Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. Phys Biol 2014 0.77
322 Inflammation in acute coronary syndromes. Cleve Clin J Med 2002 0.77
323 Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol 2004 0.77
324 Association of race with complications and prognosis following acute coronary syndromes. Am J Cardiol 2004 0.77
325 Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. Catheter Cardiovasc Interv 2006 0.77
326 Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Am Heart J 2007 0.77
327 Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol 2004 0.77
328 Lack of cardioprotective effect of naproxen. Arch Intern Med 2002 0.77
329 Pharm-econogenomics: a new appraisal. Clin Chem 2013 0.76
330 A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2005 0.76
331 Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Am J Cardiol 2008 0.76
332 Pharmacogenetics: Point-of-care genetic testing--a new frontier explored. Nat Rev Cardiol 2012 0.76
333 Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol 2006 0.76
334 Cholesterol, racial variation and targeted medicines. Nat Med 2005 0.76
335 Risk reduction with long-term clopidogrel following percutaneous coronary intervention. Eur Heart J 2004 0.76
336 Aspirin with bypass surgery--from taboo to new standard of care. N Engl J Med 2002 0.76
337 Pharmacogenomics in cardiovascular diseases. Curr Probl Cardiol 2003 0.76
338 Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Am J Cardiol 2002 0.76
339 Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am Heart J 2006 0.76
340 Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 2003 0.75
341 Impact of on-site cardiac interventional facilities on management and outcome of patients with acute coronary syndromes. Can J Cardiol 2003 0.75
342 Validity of reported genetic risk factors for acute coronary syndrome. JAMA 2007 0.75
343 Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis 2008 0.75
344 Is computed tomographic angiography prognostic in patients with cardiac symptoms? J Am Coll Cardiol 2008 0.75
345 Lack of adverse clopidogrel-atorvastatin clinical interaction. Am J Cardiol 2004 0.75
346 Atheromatous showers, periprocedural myocardial infarction, and fatality. Am Heart J 2003 0.75
347 Anticoagulation with prosthetic cardiac valves. Arch Intern Med 2003 0.75
348 Is there a genetic basis for acute coronary syndrome? Nat Clin Pract Cardiovasc Med 2007 0.75
349 Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors. Arthritis Res Ther 2002 0.75
350 Past the wall in cardiovascular R&D. Nat Rev Drug Discov 2009 0.75
351 The role of low-molecular-weight heparin in cardiovascular diseases. Prog Cardiovasc Dis 2002 0.75
352 Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Eur Heart J 2005 0.75
353 Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. Am J Cardiol 2003 0.75
354 Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention. Am J Cardiol 2006 0.75
355 Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survival. Am J Cardiol 2003 0.75
356 Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. Eur Heart J 2004 0.75
357 Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. Am J Cardiol 2002 0.75
358 Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. Am Heart J 2002 0.75
359 To truly look inside. Lancet 2016 0.75
360 Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002 0.75
361 Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial. Can J Cardiol 2011 0.75
362 Adjunctive therapy for percutaneous revascularization in acute myocardial infarction. Curr Pharm Des 2004 0.75
363 Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol 2003 0.75
364 Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. Am Heart J 2002 0.75
365 [Cardiology online: impact and pitfalls of Internet medical news]. G Ital Cardiol (Rome) 2012 0.75
366 An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis 2002 0.75
367 The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. Am Heart J 2006 0.75
368 Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med 2003 0.75
369 Pharmaceutical advertising versus research spending: are profits more important than patients? Am Heart J 2003 0.75
370 Coronary artery imaging with multidetector computed tomography: a call for an evidence-based, multidisciplinary approach. Am Heart J 2006 0.75
371 Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology 2002 0.75
372 Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. Can J Cardiol 2003 0.75
373 Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. Am J Cardiol 2002 0.75
374 Stents and sensibility. Catheter Cardiovasc Interv 2007 0.75
375 Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. Am Heart J 2010 0.75
376 Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. Am J Cardiol 2005 0.75
377 Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial. Am J Cardiol 2003 0.75